The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of R&D at Tr1X, with patients enrolling at leading stem cell transplant centers across ...

During infections, the immune system needs to distinguish foreign antigens that are expressed by invading bacteria and viruses from self-antigens that are expressed by cells of the body.

AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of multiple joints, with regulatory T (Treg) ...

Bill has been an exceptional leader in successfully guiding the company from early research into clinical development and preparing David to assume the role of CEO,” said Leon Chen, Ph.D., MBA, a ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a ...

The alliance is focusing initially on two disease areas – type 1 diabetes and inflammatory bowel disease – and revolves around Quell’s T-regulatory (Treg) cell platform, an area of ...

Four studies examine this question, delving deeply into the role of the transcription factor Foxp3 in governing Treg differentiation and function. Tregs play essential roles in immune homeostasis ...

Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as ...